Compare MLYS & BLKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | BLKB |
|---|---|---|
| Founded | 2019 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2023 | 2004 |
| Metric | MLYS | BLKB |
|---|---|---|
| Price | $31.07 | $47.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $47.33 | ★ $70.50 |
| AVG Volume (30 Days) | ★ 1.2M | 402.8K |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,136,093,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.24 | $45.81 |
| 52 Week High | $47.65 | $81.39 |
| Indicator | MLYS | BLKB |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 26.57 |
| Support Level | $28.17 | $45.81 |
| Resistance Level | $31.83 | $55.53 |
| Average True Range (ATR) | 1.67 | 2.78 |
| MACD | 0.11 | -0.62 |
| Stochastic Oscillator | 48.77 | 8.67 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.